Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05530707 |
Recruitment Status :
Completed
First Posted : September 7, 2022
Last Update Posted : January 20, 2023
|
Tracking Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | August 11, 2022 | ||||||||||
First Posted Date ICMJE | September 7, 2022 | ||||||||||
Last Update Posted Date | January 20, 2023 | ||||||||||
Actual Study Start Date ICMJE | September 5, 2022 | ||||||||||
Actual Primary Completion Date | January 19, 2023 (Final data collection date for primary outcome measure) | ||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||
Change History | |||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Descriptive Information | |||||||||||
Brief Title ICMJE | Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer | ||||||||||
Official Title ICMJE | Avaliação de Aceitabilidade dérmica, eficácia Hidratante, restauração da Barreira e equilíbrio da Microbiota da Pele atópica de um Produto Hidratante - Estudo Clínico, Instrumental e Subjetivo. | ||||||||||
Brief Summary | A unicentric, blind, non-comparative clinical study to evaluate the efficacy of a moisturizer in reducing clinical symptons of atopic dermatites in children through clinical, subjective and instrumental evaluations. | ||||||||||
Detailed Description | A unicentric, blind, non-comparative clinical study to evaluate the efficacy of a moisturizer in reducing clinical symptons of atopic skin dermatites in children through clinical, subjective and instrumental evaluations. Participants will be divided into 2 groups - (Group 1) Microbiome analysis; and (Group 2) Acceptabily and efficacy Group 1: It will be necessary 13 participants aged between 05 and 12 years old with historical of atopia The participant will remain in the study for 30 days using the product. Visits will be scheduled in D0 and D30. On both visits, samples will be collect to quantify Staphylococcus aureus using qPCR Group 2: It will be necessary 36 participants aged between 05 and 12 years old with historical of atopia The participant will remain in the study for 60 days using the product. Visits will be scheduled in D0, D7, D30 and D60. Instrumental evaluations: It will be evaluate on each visit: Skin hidration using Corneometer - D0, D7, D30, D60 Transepidermic water loss using TEWL - D0, D7, D30, D60 Skin barrier restoration using Confocal Microscopy - D0, D30, D60 Participants will respond to a subjective assessment using a questionnaire to capture possible feelings of discomfort during the study e subjective efficiency. A dermatologist will be available to monitor the participants throughout the study and respond a assessment of clinical efficiency. |
||||||||||
Study Type ICMJE | Interventional | ||||||||||
Study Phase ICMJE | Not Applicable | ||||||||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Prevention |
||||||||||
Condition ICMJE | Atopic Dermatitis | ||||||||||
Intervention ICMJE | Other: Moisturizer containing saccharide isomerate and niacinamide
Moisturizer containing saccharide isomerate and niacinamide
|
||||||||||
Study Arms ICMJE |
|
||||||||||
Publications * | Not Provided | ||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||
Recruitment Information | |||||||||||
Recruitment Status ICMJE | Completed | ||||||||||
Actual Enrollment ICMJE |
49 | ||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||
Actual Study Completion Date ICMJE | January 19, 2023 | ||||||||||
Actual Primary Completion Date | January 19, 2023 (Final data collection date for primary outcome measure) | ||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||
Sex/Gender ICMJE |
|
||||||||||
Ages ICMJE | 5 Years to 12 Years (Child) | ||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||
Listed Location Countries ICMJE | Brazil | ||||||||||
Removed Location Countries | |||||||||||
Administrative Information | |||||||||||
NCT Number ICMJE | NCT05530707 | ||||||||||
Other Study ID Numbers ICMJE | EN21-0556-01_EN22-2004-01 | ||||||||||
Has Data Monitoring Committee | No | ||||||||||
U.S. FDA-regulated Product |
|
||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||
Current Responsible Party | Farmoquimica S.A. | ||||||||||
Original Responsible Party | Same as current | ||||||||||
Current Study Sponsor ICMJE | Farmoquimica S.A. | ||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||
Collaborators ICMJE | Medcin Instituto da Pele | ||||||||||
Investigators ICMJE | Not Provided | ||||||||||
PRS Account | Farmoquimica S.A. | ||||||||||
Verification Date | January 2023 | ||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |